Gevorg Tamamyan
@GevTamamyan
Followers
2K
Following
10K
Media
167
Statuses
900
Editor-in-chief of @OncoDaily, Prof. & Chair of Ped. Oncology and Hematolgy at YSMU, President of @AsiaSIOP, President of @poem_group, CEO of @ImmoncInstitute
Armenia
Joined February 2011
Just received the new book by my dear friend @SullivanProf — The Handbook of Global Health Security, and War. With Richard, you never know where the call will find him — coordinating the evacuation of cancer patients in Eastern Europe, standing on the frontlines of care in
0
1
8
“Healthcare reform begins with listening — to patients, to professionals, to data. Only then can we build systems that are both efficient and fair.” - Valentina Prevolnik Rupel, Minister of Health of Slovenia It was an extreme pleasure and honor to host Professor Valentina
0
0
4
CACA-SPCC-OncoDaily session at #CCHIO, chaired by Dr. Ziyu Li (Peking Univ), Dr. Matti Aapro (SPCC), and Gevorg Tamamyan (OncoDaily), showcased the power of global collaboration to enhance patient survival and quality of life. @GevTamamyan @oncodaily @drkiwicj #CACA2025 #CACA25
0
1
1
An @oncodaily Magazine cover featuring one of the luminaries of French oncology — Prof. Jean-Yves Blay. @jeanyvesblay A true honor and pleasure, made even more special by discovering that we share a favorite author: Louis-Ferdinand Céline. Read the interview here:
0
0
8
🌍 Excited to share the first episode of the World Health Voices with Dr. Tamamyan podcast on @oncodaily — a new global platform where we will dive deep into the challenges shaping healthcare around the world. We’ll speak with leaders, physicians, scientists, nurses, patients,
0
1
7
🌐It was a great pleasure interviewing Lykke Hinsch Gylvin, CMO of @Boehringer, for the @oncodaily magazine's cover story! A lot of inspiration and motivation✨️ must read 👍 @Boehringer @boehringerus @Boehringer_AH @Boehringer_UKI
@CancerWorldmag @OncoDailyIO @OncoDailyGI
Lykke Hinsch Gylvin: “I Am Passionate. I Care Deeply About What I Do” “When you bring science and humanity together, that’s when real change happens.” – Dr. Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine, Boehringer Ingelheim In the November Issue of
0
0
6
Lykke Hinsch Gylvin: “I Am Passionate. I Care Deeply About What I Do” “When you bring science and humanity together, that’s when real change happens.” – Dr. Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine, Boehringer Ingelheim In the November Issue of
1
1
8
🫀Fedro Peccatori: Between Science and the Human Heart When Professor Fedro Peccatori (@fedrophd) speaks about oncology, it is never only about medicine. It is about life—in all its uncertainty, beauty, and resilience. From pioneering fertility preservation and treating
1
2
16
It is a great honor to be named a Fellow of the American Society of Clinical Oncology (FASCO) — a recognition bestowed upon ASCO members who have shown extraordinary dedication through their voluntary efforts to benefit the Society, the specialty of oncology, and, most
7
9
57
ICYMI: Prof. Alexander Eggermont shared how France’s AAC program gives patients access to #BOTBAL—“a unique combo with efficacy across multiple tumor types.” Watch his full remarks on global impact ▶️ https://t.co/KkvIE4uAng
#Immunotherapy #CancerCare #GlobalAccess
1
2
5
Working to explain to the world how and why Bioshield works. T cells and NK cells kill cancer, that’s irrefutable. Low NK cells and T cells means cancer grows, that’s irrefutable. So if there is a drug available to boost NK and T cells then there is better chance to kill
191
779
3K
Just before ESMO25, great news! Our collaborative paper with leading global colorectal cancer experts, addressing global CRC needs from the Global Cancer Movement Challenge, is now out in the OncoDaily Medical Journal! Huge thanks to everyone involved.
🌍Closing the Global Gap in Colorectal Cancer Care Colorectal cancer is a leading cause of cancer deaths worldwide - yet access to prevention, screening, and treatment remains deeply unequal across regions. 📝 The new article “Bridging the Global Divide in Colorectal Cancer
0
1
7
Join us Oct 21, 4PM ET for the next #Agenus Stakeholder Briefing—moderated by Dr. Garo Armen. Hear from industry leaders report post #ESMO2025 BOT/BAL data and learn about expanding access. 🎥 Watch live → https://t.co/bNycRwAIey
#BOTBAL #ImmunoOncology
1
1
3
It was such an honor and pleasure interviewing @TheHonGregHunt, former Minister of Health of Australia, a world-known healthcare leader, for the inagural issue of our new magazine "World Health Voices" by @oncodaily. Through thoughtful conversations and in-depth features, World
0
0
2
🏆 𝟭𝟬𝟬 𝐈𝐧𝐟𝐥𝐮𝐞𝐧𝐭𝐢𝐚𝐥 𝐏𝐞𝐨𝐩𝐥𝐞 𝐢𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝟮𝟬𝟮𝟱 – 𝐍𝐨𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐫𝐞 𝐎𝐩𝐞𝐧! 𝐖𝐞𝐥𝐜𝐨𝐦𝐞 𝐭𝐨 𝐎𝐧𝐜𝐨𝐃𝐚𝐢𝐥𝐲’𝐬 𝐨𝐟𝐟𝐢𝐜𝐢𝐚𝐥 𝐧𝐨𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫𝐦 𝐟𝐨𝐫 𝟭𝟬𝟬 𝐈𝐧𝐟𝐥𝐮𝐞𝐧𝐭𝐢𝐚𝐥 𝐏𝐞𝐨𝐩𝐥𝐞 𝐢𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲
0
10
20
Finally got my @NIH reply after 2.5 years: REJECTED❌ Cute timing- but my study’s already FUNDED COMPLETED & PUBLISHED in @JCOGO_ASCO Appreciate the reply - but oncology runs faster. You don’t🐢🚀 Full👇Nationwide Insights on Immunotherapy in Armenia https://t.co/vhecKpUvMB
13
19
140
Congrats to @amalsargsyan & @GevTamamyan! When I first got involved, my mind went straight to the stats - but from black markets to the complexities of an out-of-pocket system, this was so much more. One step towards better cancer policy in Armenia🤞 https://t.co/wUOJByOG32
2
3
8
𝟏𝟎𝟎 𝐈𝐧𝐟𝐥𝐮𝐞𝐧𝐭𝐢𝐚𝐥 𝐖𝐨𝐦𝐞𝐧 𝐢𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲: 𝐊𝐞𝐲 𝐎𝐩𝐢𝐧𝐢𝐨𝐧 𝐋𝐞𝐚𝐝𝐞𝐫𝐬 𝐭𝐨 𝐅𝐨𝐥𝐥𝐨𝐰 𝐨𝐧 𝐒𝐨𝐜𝐢𝐚𝐥 𝐌𝐞𝐝𝐢𝐚 𝐢𝐧 𝟐𝟎𝟐𝟓 Last week, on August 26th, in honor of Women’s Equality Day in the United States, commemorating the 1920 law granting
3
11
51
When it is Day 2 and 2,600 people are still live following our congress on X 😉 Yesterday, the number of live attendees reached up to a 6,000 ☺️ It was inagural Global Voices in Renal Oncology (VIRO) 2025 Congress by @OncoDaily. Chaired by @DrRanaMcKay, and 2025 Co-Chair
0
1
9
POEM President Dr. Gevorg Tamamyan "Gold September is not only about awareness, it is about action, it is about giving every child in every single country the same chance not just to survive, but to live, to dream to thrive!” #POEM
https://t.co/lUPeQ4ph8y
0
2
3